| Size | Price | Stock | Qty |
|---|---|---|---|
| 100mg |
|
||
| Other Sizes |
|
| ln Vitro |
As the precursor of coenzyme A, D-sodium pantothenate mostly contributes to the pyramid cycle and energy production via the β-oxidation pathway and TCA cycle, respectively [1].
|
|---|---|
| ln Vivo |
Valproic acid (VPA; 300, 400, and 500 mg/kg, sc)-induced conductive neural tube abnormalities are lessened by pantothenic acid (PTA; 3x10, 3x100, and 3x300 mg/kg) [2].
|
| Animal Protocol |
Animal/Disease Models: Female ICR mice, body weight 29 -35 g[2]
Doses: 3x10, 3x100 and 3x300 mg/kg (10 mL/kg, dosing volume) Route of Administration: intraperitonealon day 8.5 of gestation Injection Experimental Results: VPA Dramatically diminished (300, 400, and 500 mg/kg, sc) the risk of extracerebral malformations, while other external malformations (e.g., open eyelids) or skeletal malformations (e.g., fused, missing, or bifurcated ribs and thoracic spine fusion and sternal fusion) were not diminished. |
| ADME/Pharmacokinetics |
Absorption, Distribution and Excretion
Distribution of pantothenate from plasma into liver was very rapid; during 10 min after iv admin about 80% of dose was cleared from plasma. Total blood pantothenic acid levels were higher after oral admin of 21.6 uM/kg pantethine than after calcium pantothenate in rats but no difference in amount of bound pantothenic acid. Max concentrations were observed at 2-4.5 hr after ingestion of both groups. Total pantothenic acid excretions after 24 hr oral admin to rats were 29% and 18% after administration of pantethine and calcium pantothenate, respectively. Pantethine was more readily absorbed from GI tract than calcium pantothenate. |
| References |
[1]. Shuai Chen, et al. Metabolomic analysis of the toxic effect of chronic exposure of cadmium on rat urine. Environ Sci Pollut Res Int. 2018 Feb;25(4):3765-3774.
[2]. M Sato, et al. Pantothenic acid decreases valproic acid-induced neural tube defects in mice (I). Teratology. 1995 Sep;52(3):143-8. |
| Additional Infomation |
Mechanism of Action
... To test the functional effect of pantothenate on dermal fibroblasts, cells were cultured and in vitro proliferation tests were performed using a standardized scratch test procedure. For all three donors analyzed, a strong stimulatory effect of pantothenate at a concentration of 20 ug/mL on the proliferation of cultivated dermal fibroblasts was observed. To study the molecular mechanisms resulting in the proliferative effect of pantothenate, gene expression was analyzed in dermal fibroblasts cultivated with 20 ug/mL of pantothenate compared with untreated cells using the GeneChip Human Exon 1.0 ST Array. A number of significantly regulated genes were identified including genes coding for interleukin (IL)-6, IL-8, Id1, HMOX-1, HspB7, CYP1B1 and MARCH-II. Regulation of these genes was subsequently verified by quantitative real-time polymerase chain reaction analysis. Induction of HMOX-1 expression by pantothenol and pantothenic acid in dermal cells was confirmed on the protein level using immunoblots. Functional studies revealed the enhanced suppression of free radical formation in skin fibroblasts cultured with panthenol. In conclusion, these studies provided new insight in the molecular mechanisms linked to the stimulatory effect of pantothenate and panthenol on the proliferation of dermal fibroblasts. /Calcium pantotenate/ Therapeutic Uses Topical application of pantothenate is widely used in clinical practice for wound healing. |
| Molecular Formula |
C9H16NNAO5
|
|---|---|
| Molecular Weight |
241.21
|
| Exact Mass |
241.092
|
| CAS # |
867-81-2
|
| Related CAS # |
D-Pantothenic acid;79-83-4;Pantothenic acid-13C3,15N hemicalcium;356786-94-2;D-Pantothenic acid hemicalcium salt;137-08-6
|
| PubChem CID |
23679004
|
| Appearance |
Typically exists as solid at room temperature
|
| Boiling Point |
551.5ºC at 760 mmHg
|
| Melting Point |
171-178 °C(lit.)
|
| Flash Point |
287.3ºC
|
| Index of Refraction |
27 ° (C=5, H2O)
|
| Hydrogen Bond Donor Count |
3
|
| Hydrogen Bond Acceptor Count |
5
|
| Rotatable Bond Count |
6
|
| Heavy Atom Count |
16
|
| Complexity |
244
|
| Defined Atom Stereocenter Count |
1
|
| SMILES |
[C@H](O)(C(=O)NCCC(=O)O)C(C)(C)CO.[Na]
|
| InChi Key |
GQTHJBOWLPZUOI-FJXQXJEOSA-M
|
| InChi Code |
InChI=1S/C9H17NO5.Na/c1-9(2,5-11)7(14)8(15)10-4-3-6(12)13;/h7,11,14H,3-5H2,1-2H3,(H,10,15)(H,12,13);/q;+1/p-1/t7-;/m0./s1
|
| Chemical Name |
sodium;3-[[(2R)-2,4-dihydroxy-3,3-dimethylbutanoyl]amino]propanoate
|
| Synonyms |
Sodium D Pantothenate; Sodium D-Pantothenate
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment, avoid exposure to moisture. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
H2O : ~100 mg/mL (~414.56 mM)
DMSO : ~5 mg/mL (~20.73 mM) |
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 0.5 mg/mL (2.07 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 5.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 0.5 mg/mL (2.07 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 5.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 0.5 mg/mL (2.07 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. Solubility in Formulation 4: 120 mg/mL (497.47 mM) in PBS (add these co-solvents sequentially from left to right, and one by one), clear solution; with ultrasonication. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 4.1458 mL | 20.7288 mL | 41.4577 mL | |
| 5 mM | 0.8292 mL | 4.1458 mL | 8.2915 mL | |
| 10 mM | 0.4146 mL | 2.0729 mL | 4.1458 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
